These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38945365)

  • 21. Towards a better prediction of peak concentration, volume of distribution and half-life after oral drug administration in man, using allometry.
    Sinha VK; Vaarties K; De Buck SS; Fenu LA; Nijsen M; Gilissen RA; Sanderson W; Van Uytsel K; Hoeben E; Van Peer A; Mackie CE; Smit JW
    Clin Pharmacokinet; 2011 May; 50(5):307-18. PubMed ID: 21456631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development.
    Mahmood I
    Adv Drug Deliv Rev; 2007 Sep; 59(11):1177-92. PubMed ID: 17826864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and Immunogenicity of Frunevetmab in Osteoarthritic Cats Following Intravenous and Subcutaneous Administration.
    Walters RR; Boucher JF; De Toni F
    Front Vet Sci; 2021; 8():687448. PubMed ID: 34179175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetics of exendin-(9-39) and clinical dose selection in patients with congenital hyperinsulinism.
    Ng CM; Tang F; Seeholzer SH; Zou Y; De León DD
    Br J Clin Pharmacol; 2018 Mar; 84(3):520-532. PubMed ID: 29077992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interspecies allometric analysis of the comparative pharmacokinetics of 44 drugs across veterinary and laboratory animal species.
    Riviere JE; Martin-Jimenez T; Sundlof SF; Craigmill AL
    J Vet Pharmacol Ther; 1997 Dec; 20(6):453-63. PubMed ID: 9430769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor.
    Zhang L; Mao Y; Gao Z; Chen X; Li X; Liu Y; Xia G
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):15-26. PubMed ID: 31494843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.
    Yamazaki S; Skaptason J; Romero D; Vekich S; Jones HM; Tan W; Wilner KD; Koudriakova T
    Drug Metab Dispos; 2011 Mar; 39(3):383-93. PubMed ID: 21098644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative Prediction of Human Pharmacokinetics and Pharmacodynamics of CKD519, a Potent Inhibitor of Cholesteryl Ester Transfer Protein (CETP).
    Choi S; Han S; Jeon S; Yim DS
    Pharmaceutics; 2019 Jul; 11(7):. PubMed ID: 31311144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing the Impact of Immunogenicity and Improving Prediction of Trough Concentrations: Population Pharmacokinetic Modeling of Adalimumab in Patients with Crohn's Disease and Ulcerative Colitis.
    Ponce-Bobadilla AV; Stodtmann S; Chen MJ; Winzenborg I; Mensing S; Blaes J; Haslberger T; Laplanche L; Dreher I; Mostafa NM
    Clin Pharmacokinet; 2023 Apr; 62(4):623-634. PubMed ID: 36905528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of Human Pharmacokinetics of E0703, a Novel Radioprotective Agent, Using Physiologically Based Pharmacokinetic Modeling and an Interspecies Extrapolation Approach.
    Ge YX; Zhang Z; Yan JY; Ma ZC; Wang YG; Xiao CR; Zhuang XM; Gao Y
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and Biodistribution of 16,16 dimethyl Prostaglandin E2 in Non-Irradiated and Irradiated Mice and Non-Irradiated Non-Human Primates.
    Langevin B; Singh P; Plett PA; Sampson CH; Masters A; Gibbs A; Faria E; Triesler S; Zodda A; Jackson IL; Orschell CM; Gopalakrishnan M; Pelus LM
    Radiat Res; 2024 Jan; 201(1):7-18. PubMed ID: 38019093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection.
    Xiang H; Reyes AE; Eppler S; Kelley S; Damico-Beyer LA
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):405-15. PubMed ID: 23771513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose translation between laboratory animals and human in preclinical and clinical phases of drug development.
    Nair A; Morsy MA; Jacob S
    Drug Dev Res; 2018 Dec; 79(8):373-382. PubMed ID: 30343496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and interspecies scaling of recombinant human factor VIII.
    Mordenti J; Osaka G; Garcia K; Thomsen K; Licko V; Meng G
    Toxicol Appl Pharmacol; 1996 Jan; 136(1):75-8. PubMed ID: 8560482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a hybrid physiologically based pharmacokinetic model with drug-specific scaling factors in rat to improve prediction of human pharmacokinetics.
    Sayama H; Komura H; Kogayu M; Iwaki M
    J Pharm Sci; 2013 Nov; 102(11):4193-204. PubMed ID: 24018828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Vivo Hypoglycemic Studies of Polyherbal Phytoceuticals, Their Pharmacokinetic Studies and Dose Extrapolation by Allometric Scaling.
    De B; Bhandari K; Katakam P; Mitra A
    Curr Drug Discov Technol; 2017; 14(4):277-292. PubMed ID: 28359233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Translational PK/PD Modeling of Tumor Growth Inhibition and Target Inhibition to Support Dose Range Selection of the LMP7 Inhibitor M3258 in Relapsed/Refractory Multiple Myeloma.
    Lignet F; Esdar C; Walter-Bausch G; Friese-Hamim M; Stinchi S; Drouin E; El Bawab S; Becker AD; Gimmi C; Sanderson MP; Rohdich F
    J Pharmacol Exp Ther; 2023 Jan; 384(1):163-172. PubMed ID: 36273822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.
    de Vries Schultink AHM; Doornbos RP; Bakker ABH; Bol K; Throsby M; Geuijen C; Maussang D; Schellens JHM; Beijnen JH; Huitema ADR
    Invest New Drugs; 2018 Dec; 36(6):1006-1015. PubMed ID: 29728897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose Prediction and Pharmacokinetic Simulation of XZP-5610, a Small Molecule for NASH Therapy, Using Allometric Scaling and Physiologically Based Pharmacokinetic Models.
    Zhang L; Feng F; Wang X; Liang H; Yao X; Liu D
    Pharmaceuticals (Basel); 2024 Mar; 17(3):. PubMed ID: 38543155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans.
    Khor SP; Amyx H; Davis ST; Nelson D; Baccanari DP; Spector T
    Cancer Chemother Pharmacol; 1997; 39(3):233-8. PubMed ID: 8996526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.